Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 34

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 34
---
 us to solicit additional proxies in favor of the adoption of such proposal. In that event, we may ask stockholders to vote only upon the Adjournment Proposal and not on any other proposal discussed in this Proxy Statement. If the adjournment is for more than thirty (30) days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.

For the avoidance of doubt, any proxy authorizing the adjournment of the Annual Meeting shall also authorize successive adjournments thereof, at any meeting so adjourned, to the extent necessary for us to solicit additional proxies in favor of the adoption of any one or more of Proposal 3.

Required Vote and Recommendation

In accordance with our Certificate, Bylaws and Delaware law, and as further discussed above under “Abstentions and Broker Non-Votes”, approval and adoption of this Proposal 4 requires the affirmative vote of holders of a majority of shares present in person or represented by proxy and entitled to vote thereon. Abstentions, if any, with respect to this proposal will be counted for purposes of establishing a quorum and, if a quorum is present, any abstentions, if any, will have the same practical effect as a vote against this proposal.

<div align='center'>**THE BOARD RECOMMENDS

A VOTE “FOR” PROPOSAL 4.

23**</div>

#### EXECUTIVE OFFICERSThe following table identifies certain information about our executive officers as of April 25, 2025. Our executive officers are appointed by, and serve at the discretion of, our Board.NameAgePrincipal PositionGene Mack​51​President, Chief Executive Officer and DirectorGianluca Fuggetta​36​Senior Vice President Finance, Principal Financial Officer​Gene MackBiographical information for Mr. Mack is included above with the director biographies under the caption “Information Regarding Director Nominees and Current Directors.”Gianluca Fuggettahas served as Senior Vice President Finance and Principal Financial Officer of Gain Therapeutics since January 2025. He joined the Company in July 2022 and has served as our Principal Accounting Officer since January 2023 and was appointed as Vice President of Finance in January 2024. He previously held the position as our Principal Financial Officer from February to April 2024. Prior to these roles, Mr. Fuggetta served as our Senior Finance Director from January to December 2023, and as Finance Director